Five Years of Menopause Hormones Linked to Less Bowel Cancer
Graded Preliminary — register data on about 730,000 women over 18 years on average, but analysed looking back; other differences between the women may shape the result.
- Design
- Retrospective cohort study
- Participants
- 728,608
- Duration
- 18 years
- Funding
- Abbott Fund; Finnish Ministry of Social Affairs and Health; Finnish Academy of…
Finnish women who took menopausal hormones for five years or longer developed bowel cancer slightly less often.
Finnish women who used hormone therapy for menopause for at least five years were slightly less likely to develop bowel cancer. Their risk of cancer in the colon or rectum was 12 percent lower than in women of the same age who did not use hormone therapy. This difference lasted for more than five years after they stopped.
The researchers drew on national registers. They compared 364,304 women who used menopausal hormone therapy with the same number of women of the same age who did not. On average, the data covered 18 years. Few women in either group got the disease, a little over 1 in 100.
The type of hormone stood out. With estrogen alone, the risk was 19 percent lower. With estrogen combined with a progestogen, a hormone similar to the body's own progesterone, it was 8 percent lower. The researchers therefore suspect that estrogen mainly drives the difference. For cancer of the rectum, a lower risk showed up only after ten or more years of use. The study is based on register data. It cannot say for sure whether the hormones themselves protect or whether the women differed in other ways.
Conflict of Interest Disclosure: Several authors received lecture, consulting or travel fees from drug companies, including Gedeon Richter, Ferring and Orion Pharma.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Topics
